Cognitive dysfunction (CD) is frequently found in patients with systemic lupus erythematosus (SLE) and contributes to impairment in the patient’s quality of life.
Aim
To study CD in a sample of patients and the possible associations with cumulative damage, disease activity, clinical/serological profile, and cumulative glucocorticoid dose.
Methods
Included in this study are 103 patients with SLE and 95 controls for cognitive performance through MoCA (Montreal Cognitive Assessment) and MMSE (Mini-Mental State Examination). Disease activity was measured by SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) and cumulative organ damage by SLICC/ACR/DI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index). CES-D (Center for Epidemiological Studies-Depression) scale was used to evaluate depression. Data on clinical and serological profile, treatment, and cumulative glucocorticoid dose were also collected.
Results
Patients with SLE had worse performance in the MoCA (p = 0.009) and MMSE (p = 0.01) than controls. The MoCA results showed that visuospatial and abstraction domains (p = 0.03 and p = 0.002, respectively) were impaired, and the MMSE results showed that language and spatial orientation were reduced (p = 0.002 and p = 0.01, respectively) when compared to controls. Both questionnaires (MoCA with r = −0.29 and MMSE r = −0.21) correlated negatively with SLICC/ACR/DI and the MoCA with SLEDAI (r = −0.22). No associations were found with cumulative glucocorticoid dose, degree of depression, and clinical or serological profile.
Conclusions
According to the MoCA, visuospatial cognition and abstraction were impaired, and according to the MMSE, spatial orientation and language were impaired in patients with SLE. The CD was correlated with cumulative damage and disease activity. These findings demonstrate that both disease-activity and disease-injury associated CD is found broadly in SLE patients in a Brazilian population, supporting the prior reports of CD in other regional SLE populations.
RayesHATaniCKwanA, et al.What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Semin Arthritis Rheum2018; 48: 240–255. DOI: 10.1016/j.semarthrit.2018.02.007
2.
RaghunathSGlikmann-JohnstonYMorandE, et al.Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE. Lupus Sci Med2021; 8(1): e000580. DOI: 10.1136/lupus-2021-000580
3.
SeetDAllameenNATaySH, et al.Cognitive dysfunction in systemic lupus erythematosus: Immunopathology, clinical manifestations, neuroimaging and management. Rheumatol Ther2021; 8(2): 651–679. DOI: 10.1007/s40744-021-00312-0
4.
MizrachiMAndersonECarrollKR, et al.Cognitive dysfunction in SLE: an understudied clinical manifestation. J Autoimmun2022; 132: 102911. DOI: 10.1016/j.jaut.2022.102911
5.
AinialaHHietaharjuALoukkolaJ, et al.Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum2001; 45(5): 419–423. DOI: 10.1002/1529-0131(200110)45:5<419::aid-art360>3.0.co;2-x
6.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum1999; 42(4):599–608. DOI: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.
7.
HanlyJGLeggeAKamintskyL, et al.Role of autoantibodies and blood-brain barrier leakage in cognitive impairment in systemic lupus erythematosus. Lupus Sci Med2022; 9(1): e000668. DOI: 10.1136/lupus-2022-000668
8.
KozoraEArciniegasDBFilleyCM, et al.Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. Arthritis Rheum2008; 59(11): 1639–1646. DOI: 10.1002/art.24189
9.
AringerMCostenbaderKDaikhD, et al.2019 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis2019; 78:1151–1159. DOI: 10.1136/annrheumdis-2018-214819
10.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306. DOI: 10.1111/j.1538-7836.2006.01753.x
11.
NasreddineZSPhillipsNABédirianV, et al.The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc2005; 53: 695–699. DOI: 10.1111/j.1532-5415.2005.53221.x
12.
ApolinarioDDos SantosMFSassakiE, et al.Normative data for the Montreal cognitive assessment (MoCA) and the memory index score (MoCA-MIS) in Brazil: adjusting the nonlinear effects of education with fractional polynomials. Int J Geriatr Psychiatry2018; 33(7): 893–899. DOI: 10.1002/gps.4866
13.
FolsteinMFFolsteinSEMcHughPR, et al.“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198. DOI: 10.1016/0022-3956(75)90026-6
14.
KochhannRVarelaJSLisboaCSM, et al.The Mini Mental State Examination: review of cutoff points adjusted for schooling in a large Southern Brazilian sample. Dement Neuropsychol2010; 4(1): 35–41. DOI: 10.1590/S1980-57642010DN40100006
15.
RadloffLS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas1977; 1(3): 385–401. DOI: 10.1177/014662167700100
16.
GladmanDGinzlerEGoldsmithC, et al.The development and initial validation of the Systemic lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–369. DOI: 10.1002/art.1780390303
17.
PetriMKimMYKalunianKCOC-SELENA Trial, et al.Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med2005; 353: 2550–2558. DOI: 10.1056/NEJMoa051135
18.
DenburgSDDenburgJA. Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus2003; 12: 883–890. DOI: 10.1191/0961203303lu497oa
19.
CurtisCE. Prefrontal and parietal contributions to spatial working memory. Neuroscience2006; 139(1):173–180. doi: 10.1016/j.neuroscience.2005.04.070
AraboACostaOTronF, et al.Spatial and motor abilities during the course of autoimmune disease in (NZW x BXSB)F1 lupus-prone mice. Behav Brain Res2005; 165(1): 126–137. DOI: 10.1016/j.bbr.2005.06.038
22.
CeccarelliFPironeCMinaC, et al.Pragmatic language dysfunction in systemic lupus erythematosus patients: results from a single center Italian study. PLoS One2019; 14(11): e0224437. DOI: 10.1371/journal.pone.0224437
23.
OlsenKTylénK. On the social nature of abstraction: cognitive implications of interaction and diversity. Philos Trans R Soc Lond B Biol Sci. 2023; 378(1870): 20210361. DOI: 10.1098/rstb.2021.0361
24.
DumontheilI. Development of abstract thinking during childhood and adolescence: the role of rostro lateral prefrontal cortex. Dev Cogn Neurosci2014; 10: 57–76. DOI: 10.1016/j.dcn.2014.07.009
25.
RaghunathSGuymerEKGlikmann-JohnstonY, et al.Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms, and quality of life in systemic lupus erythematosus. Rheumatology2022; 62: 190–199. DOI: 10.1093/rheumatology/keac207
GonzálezAMassardoL. Antibodies and the brain: antiribosomal P protein antibody and the clinical effects in patients with systemic lupus erythematosus. Curr Opin Neurol2018; 31(3): 300–305. DOI: 10.1097/WCO.0000000000000549
28.
KowalCDiamondB. Aspects of CNS lupus: mouse models of anti-NMDA receptor antibody mediated reactivity. Methods Mol Biol2012; 900: 181–206. DOI: 10.1007/978-1-60761-720-4_9
29.
BarsegyanAMcGaughJLRoozendaalB. Glucocorticoid effects on working memory impairment require l-type calcium channel activity within prefrontal cortex. Neurobiol Learn Mem2023; 197: 107700. DOI: 10.1016/j.nlm.2022.107700
30.
ZanardiVAMagnaLACostallatLT. Cerebral atrophy related to corticotherapy in systemic lupus erythematosus (SLE). Clin Rheumatol2001; 20(4): 245–250. DOI: 10.1007/s100670170037
31.
BrownESJ WoolstonDFrolA, et al.Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry2004; 55(5): 538–545.
32.
TeoRDhanasekaranPTaySH, et al.Mathematical processing is affected by daily but not cumulative glucocorticoid dose in patients with systemic lupus erythematosus. Rheumatology (Oxford)2020; 59(9): 2534–2543. DOI: 10.1093/rheumatology/keaa002
33.
DenburgSDCarbotteRMDenburgJA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum1994; 37(9): 1311–1320. DOI: 10.1002/art.1780370907
34.
WangYTangJShenL, et al.Effects of dexamethasone on MRL/lpr mice with systemic lupus erythematosus complicated with cognitive dysfunction]. Zhong Nan Da Xue Xue Bao Yi Xue Ban2017; 42(3): 251–256. DOI: 10.11817/j.issn.1672-7347.2017.03.003
35.
LinXRChewPOKLimGH, et al.Montreal cognitive assessment as a screening instrument for cognitive impairment in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus2022; 31(14): 1759–1769. DOI: 10.1177/09612033221132237
36.
ShoreyCLMullaRTMielkeJG. The effects of synthetic glucocorticoid treatment for inflammatory disease on brain structure, function, and dementia outcomes: a systematic review. Brain Res2023; 1798: 148157. DOI: 10.1016/j.brainres.2022.148157
37.
AndersonEWJinYShihA, et al.Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. Lupus Sci Med2022; 9(1): e000808. DOI: 10.1136/lupus-2022-000808
38.
ZengJMengXZhouP, et al.Interferon-α exacerbates neuropsychiatric phenotypes in lupus-prone mice. Arthritis Res Ther2019; 21(1): 205. DOI: 10.1186/s13075-019-1985-9
39.
DormanGMicelliMCosentinoV, et al.Cognitive dysfunction in systemic lupus erythematosus in relation to disease activity and damage. Medicina (B. Aires)2017; 77(4): 257–260.
40.
ContiFAlessandriCPerriconeC, et al.Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS One2012; 7(3): e33824. DOI: 10.1371/journal.pone.0033824
41.
CeccarelliFPironeCMinaC, et al.Pragmatic language dysfunction in systemic lupus erythematosus patients: results from a single center Italian study. PLoS One2019; 14(11): e0224437. DOI: 10.1371/journal.pone.0224437
42.
SchmidtRAuer-GrumbachPFazekasF, et al.Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings. Stroke1995; 26: 749–754. DOI: 10.1161/01.str.26.5.749
43.
HanlyJGFiskJDSherwoodG, et al.Clinical course of cognitive dysfunction in systemic lupus erythematosus. J Rheumatol1994; 21: 1825–1831.
44.
HanlyJGCassellKFiskJD. Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum1997; 40: 1542–1543. DOI: 10.1002/art.1780400825
45.
CeccarelliFPerriconeCPironeC, et al.Cognitive dysfunction improves in systemic lupus erythematosus: results of a 10 years prospective study. PLoS One2018; 13: e0196103. DOI: 10.1371/journal.pone.0196103
46.
LövdénMFratiglioniLGlymourMM, et al.Education and cognitive functioning across the life span. Psychol Sci Public Interest2020; 21: 6–41. DOI: 10.1177/1529100620920576
47.
NantesSGSuJDhaliwalA, et al.Performance of screening tests for cognitive impairment in systemic lupus erythematosus. J Rheumatol2017; 44: 1583–1589. DOI: 10.3899/jrheum.161125
48.
ChalhoubNELuggenME. Screening for cognitive dysfunction in systemic lupus erythematosus: the Montreal cognitive assessment questionnaire and the informant questionnaire on cognitive decline in the elderly. Lupus2019; 28: 51–58. DOI: 10.1177/0961203318815299
49.
AlessiHDutraLAMariaLA, et al.Serum BDNF and cognitive dysfunction in SLE: findings from a cohort of 111 patients. Clin Rheumatol2022; 41(2): 421–428. DOI: 10.1007/s10067-021-05915-0
